A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Clinical trial NCT05028751 · TERMINATED
Trial details
- NCT number
- NCT05028751
- Sponsor
- Kronos Bio
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-05
- Primary completion
- 2024-04-09
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.